

**Project Title.** Protocol of two multicenter, prospective open label randomized CLinical trials to evaluate the effect of targeted therapy based on kidney biopsy findings in incident Caucasian IgAN patients (**CLIgAN**).

**Primary investigators.** Francesco P. Schena<sup>1,3</sup>, MD; Carlo Manno<sup>1</sup>, MD; Michele Rossini<sup>2</sup>, MD; Giovanni Strippoli<sup>1</sup>, MD; Mark Haas, MD<sup>4</sup> and on behalf of the CLIgAN investigators. <sup>1</sup> University of Bari, Italy, <sup>2</sup> Policlinic Hospital, Bari, Italy, <sup>3</sup> Schena Foundation, Policlinic, Bari Italy, <sup>4</sup> Cedars-Sinai Medical Center, Los Angeles, California, USA.

Trial Registration: ClinicalTrials.gov NCT 04662723

**Brief Description.** KDIGO guidelines suggest continuous supportive therapy (renin-angiotensin system blockers; RASBs) in IgAN patients with intermediate risk (proteinuria >0.5 g/day with normal or reduced eGFR and normal or high blood pressure). Only when proteinuria is > 1g/day and eGFR (normal at baseline) declines to >50 ml/min/ 1.73 m<sup>2</sup>, following three months of RASBs, corticosteroids combined with RASBs for six months should be administered. Based on existing trials, the KDIGO guidelines could not provide indications based on the presence of active and chronic renal lesions at time of the kidney biopsy as a potential effect modifier that could drive treatment decisions.

CLIgAN study is a program of two trials that allocates interventions based on the type of renal lesions at biopsy. The study is exploring: i) the benefits and harms of immediate administration of corticosteroids and RASBs in incident IgAN patients with active renal lesions (ACIgAN); ii) the benefit and harms of Dapagliflozin combined with RASBs in incident patients with moderate or chronic renal lesions (CHRONIgAN).

**Project status.** The enrollment started on February 2024. We are also collecting blood and urine samples during the follow-up.

We wish that same study may be designed and developed in incident Asian patients.

**Founding Source.** Italian Ministry of University (ARS 00-451). No commercial support.

#### **Preliminary publication**

F.P. Schena, G.Tripepi, M. Rossini, D.I. Abbrescia, C. Manno. Randomized clinical study to evaluate the effect of personalized therapy on patients with immunoglobulin A nephropathy. *Clin Kidney J* 15;15(5):895-902,2021 doi: 10.1093/ckj/sfab263. eCollection 2022 May.